Trial Results, Notes Exchange Offer, Consortium Formation, Market Activity Updates, and Orphan Drug Designation Grant - Research Reports on Lilly, Perrigo, Illumina, HCA and Alexion

NEW YORK, September 11, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Eli Lilly and Company (NYSE: LLY), Perrigo Company plc (NYSE: PRGO), Illumina, Inc. (NASDAQ: ILMN), HCA Holdings Inc. (NYSE: HCA) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6415-100free.

--
Eli Lilly and Company Research Reports
On September 4, 2014, Eli Lilly and Company (Lilly) announced that its basal insulin peglispro (BIL) showed consistent superiority over insulin glargine (Lantus®) with respect to reduced haemoglobin A1c (HbA1c) levels in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. In addition, significantly more patients taking BIL versus those taking insulin glargine achieved an HbA1c of less than 7%, a target for glycemic control established by the American Diabetes Association. Lilly said that Phase III trials are now complete and the Company is on track to file a submission with regulators by the end of Q1 2015. "These data are promising and give us further confidence in the clinical profile of BIL," said Enrique Conterno, President, Lilly Diabetes. The full research reports on Lilly are available to download free of charge at:

http://www.analystsreview.com/Sep-11-2014/LLY/report.pdf

--
Perrigo Company plc Research Reports
On September 2, 2014, Perrigo Company plc (Perrigo) announced an exchange offer for up to $500 million of its new 1.30% Senior Notes due 2016; $600 million of its new 2.30% Senior Notes due 2018; $800 million of its new 4.00% Senior Notes due 2023; and $40 million of its new 5.30% Senior Notes due 2043 (together the "Exchange Notes"). Under the offer, the Company intends to exchange the "Exchange Notes", registered under the Securities Act of 1933, for a like principal amount of its 1.30% Senior Notes due 2016; 2.30% Senior Notes due 2018; 4.00% Senior Notes due 2023; and 5.30% Senior Notes due 2043 (together the "Outstanding Notes"). According to Perrigo, the Exchange Notes will substantially identical to the Outstanding Notes, except that the Exchange Notes have been registered under the federal securities laws, are not subject to transfer restrictions, are not entitled to registration rights and will not provide for the payment of additional interest under circumstances relating to the timing of the Exchange Offer. The Exchange Offer will expire at 5:00 pm, New York City time on September 30, 2014. The full research reports on Perrigo are available to download free of charge at:

http://www.analystsreview.com/Sep-11-2014/PRGO/report.pdf

--
Illumina, Inc. Research Reports
On September 8, 2014, Illumina, Inc. (Illumina) announced that it has joined four world-renowned cancer centers to form Actionable Genome Consortium (AGC) -- an effort to recommend openly published standards for the widespread use of next-generation sequencing to guide decision-making in clinical oncology. According to the Company, the AGC will define the principles and content of the "cancer actionable genome" - a comprehensive description of genomic alterations that define individual patients' tumors. "The AGC represents an extraordinary gathering of experts and decision-makers in clinical and molecular oncology, pathology and technology who, by proposing the standards by which every tumor will be sequenced, will move the field of clinical oncology into the era of precision," said Rick Klausner, M.D., former Director of the National Cancer Institute and current Senior Vice President & Chief Medical Officer at Illumina. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Sep-11-2014/ILMN/report.pdf

--
HCA Holdings Inc. Research Reports
On September 8, 2014, the stock of HCA Holdings Inc. (HCA) continued to rise for the second straight session and hit a fresh 52-week high, before ending with a gain of 1.43% at $70.23. During the session, shares in HCA opened at $69.50, and fluctuated within the range of $69.35 - $70.45, with a total of 2.22 million shares changing hands. Over the last one month, the Company's stock has increased by 4.62%, compared to the S&P 500 index which rose 3.62% during the same period. Moreover, the Company's stock is also currently trading above its 50-day and 200-day moving averages of $63.86 and $53.69, respectively. The full research reports on HCA are available to download free of charge at:

http://www.analystsreview.com/Sep-11-2014/HCA/report.pdf

--
Alexion Pharmaceuticals, Inc. Research Reports
On September 8, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that its Hypophosphatasia (HPP) treatment drug asfotase alfa has been granted orphan drug designation (ODD) by Japan's Ministry of Health, Labour and Welfare (MHLW). Alexion informed that Asfotase alfa is an investigational, highly innovative, first-in-class targeted enzyme replacement therapy designed to address the underlying cause of HPP. "The orphan drug designation granted for asfotase alfa undescores the significant need for an effective treatment option for Japanese patients suffering from this severe, ultra-rare disorder," said Martin Mackay, Ph.D., Executive Vice President, Global Head of R&D at Alexion. The full research reports on Alexion are available to download free of charge at:

http://www.analystsreview.com/Sep-11-2014/ALXN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review